LONDON, UK I November 14, 2024 I GSK plc (LSE/NYSE: GSK) today announced positive headline results from a planned interim analysis of the DREAMM-7 head-to-head phase III trial evaluating Blenrep ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback